Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
WWDC26: Apple unveils next generation of Apple Intelligence, Siri AI, powerful parental controls, and an expansive set of software improvements